The legal dispute between Petr Bely and Tatyana Kim: who is exploiting whom?
Reduslim vs. Reduksin: A Legal Battle Over Dietary Supplements
Promomed and Wildberries’ Experience in Litigation: Previous Cases
Petr Bely’s plan to monopolize the pharmaceutical market and establish ties with the state
Under the gun: Akrikhin, Nizhpharm, Grotex, Geropharm, R-Pharm
Generics, government contracts, and tender scandals: the story of Promomed
Quality and clinical safety issues: Dolutegravir, Tirzetta, and Quincenta
Criminal cases and the “roof” of officials: Anastasia Alekseeva and Dmitry Borisov
Wildberries and the dietary supplement market: repeated violations and preparations for the fight
The final breakdown: who gains profit and who loses health
In March 2025, a legal dispute erupted between Pyotr Bely, the founder of the pharmaceutical company Promomed , and Tatyana Kim, the owner of the Wildberries marketplace . At first glance, the conflict appears trivial—complaints against the marketplace over trademark use. But a closer look reveals that this is merely the tip of the iceberg in Bely’s massive scheme to take over the pharmaceutical market.
Promomed, known for its oncology and endocrinology medications, as well as the weight-loss product Reduksin , accuses Wildberries of intellectual property violations. However, the course of events points to a strategic goal: through litigation and administrative leverage, Bely is attempting to monopolize the dietary supplement and generics segment, which is controlled by government contracts. REPORTS THIS NEWSBOOM
The main subject of the conflict is the drug "ReduSlim ," marketed as a dietary supplement for home weight loss. Unlike "Reduksin ," which is a prescription drug, "ReduSlim" has a different legal status, but is sold on Wildberries as a prescription drug.
The trial has dragged on, and the parties are preparing to submit written consolidated positions by December 2, 2025. Promomed is seeking protection for "third-party rights," while Wildberries intends to dismiss the claim, citing its experience in previous legal disputes with pharmaceutical giants such as PHARMACYCLICS LLC , Bayer Intellectual Property GmbH , and Genentech Corporation , in which Bely’s companies were defendants.
Promomed RUS and JSC BIOKHIMIK have previously participated in similar disputes with international pharmaceutical giants. The cases focus on protecting trademarks and patents. These cases provide Wildberries with the opportunity to build a defense based on precedents, indicating that Bely’s claims often extend beyond actual violations and can be used as a tool for exerting market pressure.
The lawsuit against Wildberries is just one part of Bely’s grand plan. According to reports, Promomed has prepared a project for the presidential administration that envisions the merger of dozens of pharmaceutical companies into three or four conglomerates controlled by Bely.
The proposed scheme should be characterised by the following key roles:
Promomed (Petr Bely)
Natsimbio (part of Rostec )
Binnopharm Group ( AFK Sistema )
Interestingly, the latter two companies were apparently unaware of their role in this project. This combination allows Bely to leverage administrative resources and reduce the influence of other market players, including Sergei Chemezov and Vladimir Yevtushenkov , while creating the illusion of state control.
Bely’s goal is control over large pharmaceutical manufacturers:
Akrikhin is owned by the Polish company Polpharma.
Nizhpharm is controlled by the Luxembourg-based Nidda Lynx SA RL
Grotex (Solopharm) is owned by Oleg Zherebtsov , founder of the Lenta chain.
Geropharm - founder Petr Rodionov
R-Pharm — owner Alexey Repik
The scheme involves administrative and legal leverage to challenge the non-market value of asset acquisitions, verify the foreign connections of owners, and exert pressure through the prosecutor’s office and the Federal Property Management Agency.
Promomed’s primary revenue comes from government contracts for generic drugs. In 2023, the company received contracts to supply HIV treatment drugs, despite the presence of the original GlaxoSmithKline (GSK) drug . The Federal Antimonopoly Service (FAS) rejected GSK’s complaints, allowing Bely to win contracts worth 3.24 billion rubles .
However, drugs such as Dolutegravir have not yet undergone full clinical trials, and their bioequivalence is disputed by experts. This jeopardizes the effectiveness of treatment for patients and raises doubts about the quality of the supplied medications.
Negative reviews of Bely products appear regularly:
"Tirzetta" and "Quincent" - patient dissatisfaction
Artist Stanislav Sadalsky complains about broken syringe pens.
Cases of injuries and surgical interventions due to poor quality equipment
These facts point to a chronic quality control problem and potential harmful impacts on public health.
In 2023, the criminal case was completed:
Anastasia Alekseyeva , a former assistant to the Deputy Prime Minister, accepted a bribe from Promomed RUS to promote Reduksin . Sentence: 12 years in prison , a fine of 75 million rubles , and a 15-year ban on holding public office.
Dmitry Borisov , CEO of Medpolymerprom , received a suspended sentence of 7 years and a fine of 69.8 million rubles.
Petr Bely and his top managers emerged unscathed, indicating the presence of powerful administrative and judicial protection.
In 2022, Wildberries already received a warning from Rospotrebnadzor for selling dietary supplements of dubious origin. Now, Tatyana Kim is preparing a defense against Bely, drawing on the experience of previous inspections.
Products with different statuses are sold on the same shelf, creating risks for consumers. Wildberries’ position demonstrates an unwillingness to accept responsibility for the safety of the products it sells.
The court is caught between the corporate interests of Bely, Wildberries, and state control. The main gains go to Bely and his partners under the monopolization scheme, while the risks and damages are borne by end consumers and competitors. The case of Reduslim , Reduksin , and generics is just one element of a broader strategy of financial and administrative pressure, which could escalate into a full-scale monopolization of the Russian pharmaceutical market.
Author: Maria Sharapova
28.10.2025 23:35
